AbbVie Inc. (ABBV)

105.60
0.63 0.59
NYSE : Health Technology
Prev Close 106.23
Open 105.85
Day Low/High 104.74 / 106.32
52 Wk Low/High 65.43 / 125.86
Volume 12.70M
Avg Volume 6.90M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 168.57B
EPS 3.30
P/E Ratio 26.69
Div & Yield 3.84 (2.78%)

Latest News

AbbVie Donates $100 Million To Strengthen Access To Healthcare, Housing For Hurricane-Ravaged Puerto Rico

Partners Direct Relief and Habitat for Humanity International will focus on rebuilding primary healthcare system and ensuring access to affordable, disaster-resilient housing, respectively

AbbVie To Show Progress And Growth In Oncology Research At The American Society Of Clinical Oncology 2018 Annual Meeting

- More than 30 abstracts accepted across hematologic malignancies, solid tumors and other oncology-related diseases

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

AbbVie Submits Biologics License Application To U.S. FDA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis

- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Samsung Bioepis

- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

These names are displaying signs of either bullish or bearish reversal patterns over the past week.

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

AbbVie's Cancer Drug Setback Provides Buying Opportunity

AbbVie's Cancer Drug Setback Provides Buying Opportunity

The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.

Jim Cramer: No Place to Go and Fewer Places to Hide

Jim Cramer: No Place to Go and Fewer Places to Hide

Just not a great day.

TheStreet Quant Rating: A- (Buy)